From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Human
Target TNFα
Clinical data
Trade names Simponi
AHFS/Drugs.com monograph
MedlinePlus a610010
Licence data EMA:Link, US FDA:link
Legal status
Routes of
Subcutaneous injection
CAS Number 476181-74-5 N
ATC code L04AB06
KEGG D04358 YesY
Chemical data
Formula C6530H10068N1752O2026S44
Molecular mass 147 kDa
 N (what is this?)  (verify)

Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5] Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.

In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[6] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[7][8][9]

Clinical trials[edit]

Rheumatoid arthritis[edit]

Large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[10]